Nanomedicines in the pediatric therapy: Tribulation and road ahead

Abstract

Nanotechnology has emerged as a critical technique for overcoming medicines' primary (bio)pharmaceutical disadvantages and enabling active or passive targeting of certain cells and organs. Majority of pediatric treatments are based on adult clinical experience. However, a solid concept that medication pharmacokinetics and therapeutic outcomes differ in children and adults. The interaction of certain medicines with their target receptors, varies with the maturity of various organs and systems. Usual observations are seen for toxic-side and adverse effects. Implementing innovative technologies in the pediatric population (e.g., nanotechnology) becomes exceedingly difficult in this environment. The article aims to deliver an overview of numerous initiatives to utilise nanotechnology to cure illnesses in children. We first discuss basic in vitro research through preclinical and clinical trials aimed at treating children infectious illnesses and paediatric solid tumours using nanotechnology, despite little existing literature on this subject. Finally, future perspectives of nanomedicine for pediatric population are elaborated.